Immix Biopharma, Inc. (IMMX) is a global and important biotherapeutics firm developing tissue specific therapeutics. The company’s clinical pipeline targets cancers and immumo-dysregulatory disorders. One of the lead candidates is IMX-110 in Phase 1/2 trials for soft tissue sarcoma and rhabdomyosarcoma treatment. TME Normalization technology cuts the tumor and its metabolic growth pathways.
The price of IMMX stock during the regular trading on January 25, 2022 was $4.12 with a dip of 2.6%. The stock first showed over 10% gains in the premarket on January 26, 2022, but at last check, it was slightly down by 0.48%.
IMMX: Events and Happenings
On January 25, 2022, IMMX reported the outcomes of IMX-110 + anti-PD-1 combination. It increased medium survival range to 63-day in a mouse model. The mice developed its peculiar pancreatic tumor and had an undamaged immuno-regulatory platform. On January 25, 2022, the company filed S-8 form with the SEC regarding its securities registration.
IMMX reported hopeful clinical studies safety results on January 19, 2022. The company demonstrated full completion of IMX-110 therapeutic sequences. The company also reported no disruptions related to the drug.
On January 12, 2022, IMMX reported the 50% response-rate results of IMX-110 in a mouse model for soft tissue sarcoma studies. The response was evaluated by RECIST 1.1 standard with development evaluated after one therapeutic cycle.
IMMX reported on January 06, 2022, about its event regarding Investors Day, which will be held on February 1, 2022. On January 03, 2022, IMMX reported about the grant of Rare Pediatric Disease status by FDA to IMX-110.
On December 20, 2021, IMMX reported the closure of its preliminary public offering of 4,200,000 shares. The public offering price of the shares of its common stock was $5.00. The net proceeds resulted from the offering were $21,000,000. Additionally, IMMX also granted the acquisition of extra 630,000 shares at the public price.
Conclusion
IMMX stock performed well during the last six months period as it swelled 12% during the period. The current decrease in stock can be attributed to its recent SEC filing regarding securities to be offered to employees in employee benefit plans. The analysts are optimistic that the company will reap the benefits of its important strategic collaborations.
